RxDoctor Payments Data

Kyle Weld, MD

Urology · San Antonio, TXNPI 1154309573

Payments from drug & device makers

$1,693in general payments, 2019–2025

Across 48 payments — averaging $35.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neotract Inc.$873
  • Dendreon Pharmaceuticals LLC$151
  • Boston Scientific$150
  • Sumitomo Pharma America, Inc.$134
  • Urovant Sciences Inc$68
  • Johnson & Johnson$60
  • plus $258 from 11 others

What the payments were for

  • Speaking & faculty fees$151%
  • Travel & lodging$54432%
  • Food & beverage$1,12867%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,693 in reported general payments places this provider in the 30th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$330,618
Medicare patients
886
Services billed
5,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide73$1,014,059
ErleadaApalutamide20$275,029
MyrbetriqMirabegron168$185,253
GemtesaVibegron72$82,521
OrgovyxRelugolix11$27,692
Tamsulosin Hcl761$9,856
Solifenacin Succinate35$5,444
Oxybutynin Chloride ErOxybutynin Chloride273$4,512
Finasteride236$3,314
NitrofurantoinNitrofurantoin Macrocrystal50$3,077
Estradiol45$2,746
Silodosin40$2,467
Testosterone Cypionate43$2,220
Alfuzosin Hcl ErAlfuzosin Hcl56$1,522
Desmopressin Acetate25$1,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$60$275,02920 claims
Sumitomo Pharma America, Inc.Gemtesa, Orgovyx$134$110,21383 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 878 urology providers in Texas.

Other urology in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →